ACAP2

Across TCGA pan-cancer cohorts, ACAP2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ACAP2 data layer compared with 24 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher ACAP2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ACAP2 expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

CCRCC, COAD, and GBM are the cancer types where ACAP2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	All	0.647	0.815	.012	14	view →
COAD	DFS	Median	All	0.889	1.000	.024	12	view →
GBM	DFS	Tertile	All	0.653	0.877	.005	9	view →
PDAC	DFS	Median	All	0.223	0.400	.039	4	view →
LUAD	OS	Quartile	All	0.848	0.473	.011	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ACAP2–CCRCC (DFS)

Open the CCRCC breakdown →